EVGN Stock Overview
Operates as a computational biology company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Evogene Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪1.57 |
| 52 Week High | ₪10.40 |
| 52 Week Low | ₪1.20 |
| Beta | 1.13 |
| 1 Month Change | 11.74% |
| 3 Month Change | -39.03% |
| 1 Year Change | -83.26% |
| 3 Year Change | -90.00% |
| 5 Year Change | -90.71% |
| Change since IPO | -88.37% |
Recent News & Updates
Recent updates
Evogene unit files for EPA approval of bio-fungicide LAV.311 for fruit rots
Oct 12Evogene unit launches 2nd-gen medical cannabis products in Israel
Sep 21Lavie Bio appoints Guri Oron as CEO
Sep 14Evogene GAAP EPS of -$0.42 misses by $0.23, revenue of $0.55M beats by $0.33M
Aug 31Evogene regains compliance with Nasdaq's minimum bid price requirement
Aug 25Evogen stock rises after unit gets $10M investment from ICL under collaboration agreement
Aug 17Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus
Mar 22Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)
Mar 03Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical Market
Sep 14Evogene: Bullish With Canonic's Entry Into Israeli Medical Cannabis Markets
Jun 16Evogene EPS beats by $0.01, beats on revenue
May 26Evogene unit - Canonic inks cultivation deal for medical cannabis varieties
Dec 23AgPlenus reaches a 'Lead' Stage in its mode-of-action herbicide program
Dec 15Evogene: Q3 Update And Upcoming Catalysts
Nov 30Shareholder Returns
| EVGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -17.4% | -0.1% | -0.5% |
| 1Y | -83.3% | -6.4% | 23.2% |
Return vs Industry: EVGN underperformed the US Biotechs industry which returned -6.4% over the past year.
Return vs Market: EVGN underperformed the US Market which returned 23.2% over the past year.
Price Volatility
| EVGN volatility | |
|---|---|
| EVGN Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: EVGN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EVGN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 142 | Ofer Haviv | www.evogene.com |
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Evogene Ltd. Fundamentals Summary
| EVGN fundamental statistics | |
|---|---|
| Market cap | US$11.04m |
| Earnings (TTM) | -US$23.51m |
| Revenue (TTM) | US$7.48m |
1.5x
P/S Ratio-0.5x
P/E RatioIs EVGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVGN income statement (TTM) | |
|---|---|
| Revenue | US$7.48m |
| Cost of Revenue | US$2.33m |
| Gross Profit | US$5.15m |
| Other Expenses | US$28.67m |
| Earnings | -US$23.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.46 |
| Gross Margin | 68.90% |
| Net Profit Margin | -314.43% |
| Debt/Equity Ratio | 0% |
How did EVGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 02:38 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Evogene Ltd. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Benjamin Haynor | Alliance Global Partners |
| Kristen Kluska | Cantor Fitzgerald & Co. |